drugset

drugset / Trial / NCT06468956

Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

NCT06468956 ↗

Phase 3 Active not recruiting 652 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.

Timeline

Start: 2024-06-14
Primary completion: 2026-03-31
Completion: 2026-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1819	Monoclonal antibody	—	—

Indications